The Board of Directors has decided to postpone the application for changing trading list to NASDAQ OMX

The decision means that the planned change of trading venue for SyntheticMR's share to NASDAQ OMX Stockholm will be postponed to the future. The company has recently made a CEO change and the resources will be focused on the business operations to further establish the company's products in the global market.

For additional information, please contact Fredrik Jeppsson, CFO and Head of Investor Realtions, SyntheticMR AB, +46 72 303 13 39 or Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan – to improve patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com. 

This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 17th, 2019